S&P 500   5,079.35 (+0.19%)
DOW   38,912.18 (-0.09%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.12 (+0.10%)
META   486.48 (+0.51%)
GOOGL   136.92 (+0.40%)
AMZN   174.80 (+0.95%)
TSLA   199.78 (-1.12%)
NVDA   789.24 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.59 (+6.83%)
BABA   74.09 (-0.67%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.45 (-0.29%)
CGC   3.29 (-2.08%)
GE   155.71 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.30 (-13.83%)
PFE   26.74 (-1.11%)
PYPL   60.21 (-0.07%)
XOM   104.66 (+0.33%)
S&P 500   5,079.35 (+0.19%)
DOW   38,912.18 (-0.09%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.12 (+0.10%)
META   486.48 (+0.51%)
GOOGL   136.92 (+0.40%)
AMZN   174.80 (+0.95%)
TSLA   199.78 (-1.12%)
NVDA   789.24 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.59 (+6.83%)
BABA   74.09 (-0.67%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.45 (-0.29%)
CGC   3.29 (-2.08%)
GE   155.71 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.30 (-13.83%)
PFE   26.74 (-1.11%)
PYPL   60.21 (-0.07%)
XOM   104.66 (+0.33%)
S&P 500   5,079.35 (+0.19%)
DOW   38,912.18 (-0.09%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.12 (+0.10%)
META   486.48 (+0.51%)
GOOGL   136.92 (+0.40%)
AMZN   174.80 (+0.95%)
TSLA   199.78 (-1.12%)
NVDA   789.24 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.59 (+6.83%)
BABA   74.09 (-0.67%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.45 (-0.29%)
CGC   3.29 (-2.08%)
GE   155.71 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.30 (-13.83%)
PFE   26.74 (-1.11%)
PYPL   60.21 (-0.07%)
XOM   104.66 (+0.33%)
S&P 500   5,079.35 (+0.19%)
DOW   38,912.18 (-0.09%)
QQQ   437.05 (+0.41%)
AAPL   179.78 (-0.90%)
MSFT   408.12 (+0.10%)
META   486.48 (+0.51%)
GOOGL   136.92 (+0.40%)
AMZN   174.80 (+0.95%)
TSLA   199.78 (-1.12%)
NVDA   789.24 (+1.62%)
NIO   5.65 (+4.05%)
AMD   188.59 (+6.83%)
BABA   74.09 (-0.67%)
T   16.97 (+0.06%)
F   12.38 (+0.65%)
MU   89.45 (-0.29%)
CGC   3.29 (-2.08%)
GE   155.71 (+0.06%)
DIS   111.54 (+0.67%)
AMC   4.30 (-13.83%)
PFE   26.74 (-1.11%)
PYPL   60.21 (-0.07%)
XOM   104.66 (+0.33%)

Orchard Therapeutics (ORTX) Earnings Date, Estimates & Call Transcripts

$16.70
0.00 (0.00%)
(As of 01/24/2024)
Skip Charts & View Estimated and Actual Earnings Data

ORTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ORTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Orchard Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:($5.25) EPS
Next Year EPS Consensus Estimate: ($4.85) EPS

ORTX Earnings Date and Information

Orchard Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off prior year's report dates.

Orchard Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/4/2024
Estimated)
------- 
11/13/2023Q3 2023($1.30)($0.15)+$1.15($0.15)$6.63 million$6.30 million
8/3/2023Q2 2023($1.67)($0.07)+$1.60($0.07)$5.20 million$7.31 million
5/15/2023Q1 2023($1.61)($0.12)+$1.49($0.12)$6.48 million$1.24 million
3/6/2023Q4 2022($1.80)($0.60)+$1.20($0.60)$5.38 million$6.99 million
11/14/2022Q3 2022($2.30)($3.70)($1.40)($0.37)$4.12 million$5.78 million
8/4/2022Q2 2022($2.50)($4.00)($1.50)($0.40)$2.70 million$4.37 million
5/12/2022Q1 2022($2.50)($3.50)($1.00)($0.35)$4.97 million$5.52 million
3/30/2022Q4 2021($2.90)($2.90)-($0.29)$0.65 million$0.48 million  
11/4/2021Q3 2021($2.50)($2.90)($0.40)($0.29)$5.82 million$1.19 million
8/4/2021Q2 2021($3.20)($2.90)+$0.30($0.29)--
5/13/2021Q1 2021($3.30)($3.10)+$0.20($0.31)--
3/1/2021Q4 2020($3.40)($3.40)-($0.34)--












Orchard Therapeutics Earnings - Frequently Asked Questions

When is Orchard Therapeutics's earnings date?

Orchard Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off last year's report dates. Learn more on ORTX's earnings history.

How much revenue does Orchard Therapeutics generate each year?

Orchard Therapeutics (NASDAQ:ORTX) has a recorded annual revenue of $22.66 million.

How much profit does Orchard Therapeutics generate each year?

Orchard Therapeutics (NASDAQ:ORTX) has a recorded net income of -$150.66 million. ORTX has generated -$0.94 earnings per share over the last four quarters.

What is Orchard Therapeutics's EPS forecast for next year?

Orchard Therapeutics's earnings are expected to grow from ($5.25) per share to ($4.85) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ORTX) was last updated on 2/29/2024 by MarketBeat.com Staff